404
Glucagon Market Report
Global Glucagon Market, Dynamics, Market Analysis
The Global Glucagon Market report is segmented By Product Type (Inject Glucagon, Nasal Glucagon), Application (Emergency Use, General Use, Diagnostics & Motility, Others), and Region. It also covers the COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Glucagon market. The historic years considered for the study are 2016-2019, base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The glucagon market is expected to witness an impressive growth of 6.1% CAGR in the coming years.
Fresenius SE & Co. KGaA (Germany), Eli Lilly & Co. (The U.S), Novo Nordisk A/S (Denmark), Xeris Pharmaceuticals, Inc. (The U.S), Svar Life Science AB (Sweden), Taj Pharmaceuticals Ltd. (India), Pfizer Inc (The U.S), Amgen Inc. (The U.S), Avalon Pharma Private Limited (India), Bachem Holding AG (Switzerland) and Fujifilm Holdings Corporation (Japan) are among the key players in the glucagon market.
The glucagon market is expected to reach USD 689.2 million in the foreseeable future.
North America is expected to remain dominant in the glucagon market in the coming years.
The inject glucagon segment accounted for the largest share of the glucagon market in 2020.
Increasing prevalence of hypoglycaemia among people suffering from diabetes, growing emphasis on the development of innovative products such as non-injectable emergency glucagon, development of advanced drugs and therapies to treat hypoglycaemia are the factors driving the growth of glucagon market.
Glucagon manufacturers, Glucagon suppliers, Glucagon distributors, Organizations, Government bodies are the target audience in the glucagon market.